Abstract: An object of the present invention is to provide a protein having dipeptide synthesizing activity with improved substrate specificity, and a method in which the protein or a microorganism having ability to produce the protein is used to efficiently produce a target dipeptide while reducing a by-product dipeptide produced in addition to the target dipeptide. According to the present invention, a protein consisting of an amino acid sequence obtained by substituting, with other amino acid residues, amino acid residues corresponding to one or more amino acid residues selected from the group consisting of amino acid residues at positions 107, 108, and 110 in an amino acid sequence set forth in SEQ ID NO: 2, or a mutant protein or a homologous protein of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is provided, and a microorganism producing the protein can be used to efficiently produce a dipeptide.

Abstract: A method of preparing an inorganic binder for medical use according to an embodiment of the present disclosure includes preparing a starting material using a-TCP powder and phosphate powder each of which has a predetermined particle size, producing a paste having a predetermined viscosity that is suitable for formation of a molded article having a predetermined shape by homogeneously mixing the starting material, adding water or saline to the homogeneously mixed starting material, and kneading the resulting mixture, subjecting the molded article to hydration reaction, and washing and drying the molded article having undergone the hydration reaction to obtain an inorganic binder containing OCP and HA crystal phases.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of neuroinflammation including eleutheroside B as an active ingredient, and more particularly, to a pharmaceutical composition for treating neuroinflammatory disease in patients with the increased activity of astrocytes or microglia, comprising eleutheroside B or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a peptide provided herein includes at least one peptide unit, and the peptide unit may include at least one B-cell epitope, at least one Th epitope, and an appropriate number of auxiliary parts. The peptide unit is a portion designed to uniformly induce only the intended antibody while exhibiting a certain level of immunogenicity in the body of a subject. In addition, the peptide unit is designed with a relatively short length, and thus has the characteristics of easy synthesis and a low production cost. The peptide has properties suitable for use as an immunotherapeutic due to the characteristics of the peptide unit described above. In the present specification, the design principles of the peptide and the peptide unit are disclosed in detail.

Abstract: An object of the present invention is to provide a method for efficiently producing a fucose-containing carbohydrate by using a protein associated with transport of a fucose-containing carbohydrate and a microorganism having an ability to produce the protein. The present invention relates to any one protein of [1] a protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or 4, [2] a mutant protein having a transporting activity for a fucose-containing carbohydrate and consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 2 or 4, and [3] a homologous protein having a transporting activity for a fucose-containing carbohydrate and consisting of an amino acid sequence having an identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2 or 4.

Abstract: The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.

Abstract: The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.

Abstract: The present invention relates to fatty acid-modified polymer nanoparticles, and a use thereof. In the present invention, nanoparticles having embedded calcium carbonate crystals can be formed using a biocompatible polymer and an adipocyte-targeting ligand (a fatty acid) to minimize delivery to surrounding cells and tissues other than adipocytes and maximize the embedding of the nanoparticles into adipocytes. The nanoparticles according to the present invention can be produced as an injectable preparation, and can be applied to local lipolysis supplements or diet and beauty products that break down localized fat.

Abstract: A composition for a FDM 3D printer is disclosed. The composition contains bioglass and a biocompatible polymer resin. In addition, a FDM 3D printer molded article having a laminated strut structure, in which the composition for the FDM 3D printer is injected into four layers, is disclosed.

Abstract: Provided is a method for more efficiently sorting out genetically modified cells. Specifically provided are a method for selecting a cell including a modified gene on a target locus in a genome, a method for producing a cell including a modified gene on a target locus in a genome, and an animal including a modified gene on a target locus in a genome, and a kit for selecting an animal including a modified gene on a target locus in a genome and cells including a modified gene on a target locus in a genome.

Abstract: A health improvement path search device including: a first model generating unit configured to generate a first model predicting a value of a health index; a second model generating unit configured to generate a second model deriving a presence probability; and a path searching unit configured to derive the value of the health index and the presence probability corresponding to each measurement target value specify a plurality of paths transitioning to each of the measurement target values from the current values as start points, specify paths in which the value of the health index at an end point is improved from the current value of the health index among the plurality of paths as candidate paths, and specify a path for which a product of the presence probabilities of the measurement target values included in the candidate path is a maximum as a health improvement path.

Abstract: Provided are a bone graft composition and a preparation method thereof, and more particularly, a bone graft composition provided in the form of a putty formulation by mixing calcium phosphate compound particles with hydrogel, having excellent physical properties, which is easy to inject, and which maintains its structure even in an in vivo environment after implantation, thereby enabling sustained release of a drug loaded therein.

Abstract: The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-CoV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.

Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody, a CAR-T cell expressing the chimeric antigen receptor, a pharmaceutical composition including the same and a method for preventing or treating a disease mediated by B cells using the pharmaceutical composition. In the present invention, it was confirmed that the CD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells effectively killed cells expressing CD22. Furthermore, the humanized antibody-based CD22-CAR-T cells specifically binding to CD22 of the present invention can be usefully utilized as a composition for preventing or treating a disease related to the expression of CD22 or a disease related to B cells.

Abstract: The present invention relates to: a novel 4-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Abstract: A pharmaceutical composition for preventing or treating cancer, which is associated with a KRAS mutation and exhibits resistance to an EGFR-targeted therapeutic agent is disclosed. The pharmaceutical composition can be useful for treatment of patients with cancer which has the KRAS mutation and exhibits resistance to cetuximab that is an anticancer therapeutic agent. A method for providing information on an anticancer treatment and/or enhancing cancer treatment by identifying a KRAS mutation and optionally additionally a RON mutation are disclosed.

Abstract: A tumor complex antigen, a multivalent dendritic cell (DC) vaccine, and a use thereof are provided. In the present disclosure, monocytes of a patient are stimulated in vitro, loaded with a variety of tumor cell lysates with strong immunogenicity against different Epstein-Barr virus (EBV)-associated tumors, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists to obtain a complete DC vaccine with corresponding tumor antigens. The DC vaccine can be injected back into the patient to activate an immune system, stimulate innate immunity (such as inducing natural killer (NK) cells), and stimulate lymphocytes to produce an acquired immune response and cytotoxic T cells, thereby accurately killing tumor cells. Compared with radiotherapy and chemotherapy, the DC vaccine is particularly safe and has almost no side effects. In addition, the production of the DC vaccine involves a short production cycle of about 1 week and a low cost.

Abstract: The present invention relates to: a novel 6-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Abstract: An object of the invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients is provided.

Abstract: An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.